Next |
home / stock / cvac / cvac message board
Subject | By | Source | When |
---|---|---|---|
$CVAC CureVac NV | mick | investorshub | 04/30/2023 10:27:40 PM |
$CVAC CureVac NV | mick | investorshub | 04/15/2023 7:10:09 PM |
$CVAC CureVac NV | mick | investorshub | 04/15/2023 2:57:33 PM |
$CVAC CureVac NV | mick | investorshub | 04/15/2023 2:57:32 PM |
$CVAC CureVac NV | mick | investorshub | 02/26/2023 11:52:14 PM |
$CVAC CureVac NV | mick | investorshub | 02/05/2023 11:46:59 PM |
znewcar1: $CVAC 20% v5,6M c12.49 f190,283M H12.60 ML5.63 YL9.83 | znewcar1 | investorshangout | 01/10/2023 10:35:11 PM |
znewcar1: $CVAC 25% v6,7M c10.36 f190,283M H11.14 gapGoFade S10? | znewcar1 | investorshangout | 01/09/2023 11:10:36 PM |
znewcar1: $CVAC 29% v2,7M C8.26 f190,283M H8.30 ml5.63 | znewcar1 | investorshangout | 01/06/2023 10:04:06 PM |
it is relative CureVac ($CVAC) Receives a Buy | mick | investorshub | 12/20/2022 12:30:23 AM |
$CVAC CureVac NV | mick | investorshub | 12/20/2022 12:28:58 AM |
i think $CVAC is ah buyout candidate /\ | mick | investorshub | 12/20/2022 12:28:58 AM |
$CVAC CureVac NV | mick | investorshub | 12/18/2022 10:35:11 PM |
$CVAC CureVac NV | mick | investorshub | 10/23/2022 5:49:02 PM |
$CVAC CureVac N.V. | mick | investorshub | 08/31/2022 10:29:19 PM |
we don't show quote ????? | mick | investorshub | 08/31/2022 10:28:07 PM |
we don't show quote ????? | mick | investorshub | 08/31/2022 10:28:06 PM |
CureVac ($CVAC) Receives a Buy from Berenberg Bank | mick | investorshub | 08/31/2022 10:26:54 PM |
$CVAC CureVac NV | mick | investorshub | 07/18/2022 12:08:11 AM |
Interesting new Beneficial Owners recently. Taken an | sdy | investorshub | 07/01/2022 7:06:38 PM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strain Study initiated following previously reported interim data from Phase 2 Part of combined Phase 1/2 study in seasonal influenza Composition of vaccine ca...
Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year end U.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1) vaccine currently in Phase 1 development; candidate jointly developed with GSK Settlement wi...
CureVac N.V. (NASDAQ: CVAC) is one of today's top gainers. The company's shares have moved 23.1% on the day to $4.05. CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing pr...